Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey

Background: Portal hypertension (PHT) and hepatocellular carcinoma (HCC) are two major com-plications of cirrhosis that are closely linked and impact patients prognosis, particularly acute variceal bleeding (AVB). Therefore, PHT screening and AVB prophylaxis are major issues to improve the outcome of the patients, but practices may vary among physicians.Methods: We submitted hepatologists, gastroenterologists and digestive oncologists to a ques-tionnaire of 70 items about PHT screening and management to evaluate their practice. Results: 95 out of 847 physicians responded to the questionnaire (hepatologists 63.2%, Oncolo-gists/gastroenterologists 36.8%). In patients with advanced HCC, PHT was assessed by endoscopy in 80.0% of cases. HCC progression motivated a new for 12.6% of respondents while no intent to control was declared for 49.5% of them.AVB primary prophylaxis for large size esophageal varices (EV) was impacted by the presence of red marks at endoscopy. In the absence of a red mark, prophylaxis with non-selective beta-blockers (NSSB) was proposed in 70.5% of cases for patients undergoing TKI and 63.2% undergoing Atezolizumab/Bevacizumab, whereas the combination of endoscopic band ligation (EBL) and NSBB was preferred in 41.1% of patients undergoing TKI versus 53.7% undergoing Atezolizumab/ Bevacizumab in case of a red mark.The initiation of a systemic treatment was lower in patients with an history of AVB <6 months, which was even more significant for Atezolizumab/Bevacizumab combination (51.6%) compared to tyrosine kinase inhibitors (72.6%) (p<0.001). Atezolizumab/Bevacizumab was initiated in 43% of participants in case of AVB <6 months versus 95% if >6 months (p<0.001).In case of AVB on Atezolizumab/Bevacizumab, 43.2% continued the treatment after regression of EV, 24.2% continued Atezolizumab alone and 14.7% permanently stopped the treatment.Conclusion: Strategies for screening and management of PHT in advanced HCC remain very het-erogeneous among physicians, suggesting the need to improve PHT knowledge and dedicated studies for advanced HCC.(c) 2022 Published by Elsevier Masson SAS.